In a recent article on Outsourcing Pharma, Dan Stanton discusses the new EU clinical trial regulation and it’s intention to simplify the approval process in hopes of making the EU more accessible and desirable for clinical research. The new regulation will take action near the end of 2017 and it is said to be “one of the most important changes in the field of clinical trials in the last decade,” by Martine Dehlinger-Kremer, global VP of medical and regulatory affairs at SynteractHCR.
While the new regulation brings prosperity for the European clinical trial industry, it will also cause greater centralization, shortened timelines, and limited resources for clinical research organizations (CROs).
To read Stanton’s article, click here.